Skip to main content
      #GCA & #PMR @ACRheum #ACR25
      #gamechangers #ACRBest
      Yr 2 Select-GCA abst#776
      #upadacitinib in yr2 of GCA REDUCES flar

      Janet Pope Janetbirdope

      4 months ago
      #GCA & #PMR @ACRheum #ACR25 #gamechangers #ACRBest Yr 2 Select-GCA abst#776 #upadacitinib in yr2 of GCA REDUCES flares HELPFUL info ?ability to get drug for 2 yrs hopefully Failed Phase3 RCT of #secukinumab in #GCA helped #PMR abst#1175 & +Ph3 for PMR REPLENISH RCT @RheumNow https://t.co/5lH6HXhnfg
      What happens if you have #axSpA & concomitant #FM?

      Pts with both have less TNFi retention,
      -residual pain may lead

      Janet Pope Janetbirdope

      4 months ago
      What happens if you have #axSpA & concomitant #FM? Pts with both have less TNFi retention, -residual pain may lead to d/c Rx. Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA. #ACR25 @RheumNow abst#534
      Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will

      David Liew drdavidliew

      4 months ago

      Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will this be a problem for autoimmune CAR-T as we gain more experience? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/RhhdOiyEAX

      When should you order a renal bx in suspected #LN?

      Active urinary sediment
      Used to be #UPCR 500g/g or more
      Abst#772 loo

      Janet Pope Janetbirdope

      4 months ago
      When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more Abst#772 looked at UPCR 250g/g to 499 71% + LN and half needed Rx esp if Low C3,C4 Black race Petri, Baltimore #lupus #cohort #ACR25 @ACRheum @RheumNow
      Next Generation T-Cell Engager: The Future

      Dr. Alfred Kim reviews abstract 0001 presented at #ACR25.

      https://t.co/vmZ

      Dr. John Cush RheumNow

      4 months ago
      Next Generation T-Cell Engager: The Future Dr. Alfred Kim reviews abstract 0001 presented at #ACR25. https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l
      A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
      After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At this year’s ACR25 Convergence Conference in Chicago, not one but two drugs presented their efficacy and safety data in patients with moderate to severe disease activity as defined by ESSDAI score ≥ 5 points.
      At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
      RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All covera

      Dr. John Cush RheumNow

      4 months ago
      RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
      CAR-T Cell Therapies Show Promise for Autoimmune Disease

      Two pioneering studies presented at #ACR25 spotlight the poten

      Dr. John Cush RheumNow

      4 months ago
      CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
      Meta analysis evaluating age specific incidence across multiple registries (n=882)

      Incidence 9.3 for women & 1.4 fo

      Mike Putman EBRheum

      4 months ago
      Meta analysis evaluating age specific incidence across multiple registries (n=882) Incidence 9.3 for women & 1.4 for men per 100k person-years 1. Wider distribution than I would have guessed 2. Much less age-dependency for men @RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V
      ×